Detalles de la búsqueda
1.
Effects of esketamine on patient-reported outcomes in major depressive disorder with active suicidal ideation and intent: a pooled analysis of two randomized phase 3 trials (ASPIRE I and ASPIRE II).
Qual Life Res
; 32(11): 3053-3061, 2023 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-37439961
2.
Esketamine Nasal Spray for Rapid Reduction of Depressive Symptoms in Patients With Major Depressive Disorder Who Have Active Suicide Ideation With Intent: Results of a Phase 3, Double-Blind, Randomized Study (ASPIRE II).
Int J Neuropsychopharmacol
; 24(1): 22-31, 2021 01 20.
Artículo
en Inglés
| MEDLINE | ID: mdl-32861217
3.
Esketamine Nasal Spray for the Rapid Reduction of Depressive Symptoms in Major Depressive Disorder With Acute Suicidal Ideation or Behavior.
J Clin Psychopharmacol
; 41(5): 516-524, 2021.
Artículo
en Inglés
| MEDLINE | ID: mdl-34412104
4.
Correction: Double-blind, placebo-controlled, dose-ranging trial of intravenous ketamine as adjunctive therapy in treatment-resistant depression (TRD).
Mol Psychiatry
; 25(7): 1604, 2020 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-30617276
5.
Double-blind, placebo-controlled, dose-ranging trial of intravenous ketamine as adjunctive therapy in treatment-resistant depression (TRD).
Mol Psychiatry
; 25(7): 1592-1603, 2020 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-30283029
6.
The effect of esketamine in patients with treatment-resistant depression with and without comorbid anxiety symptoms or disorder.
Depress Anxiety
; 38(11): 1120-1130, 2021 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-34293233
7.
Perinatal depressive symptoms often start in the prenatal rather than postpartum period: results from a longitudinal study.
Arch Womens Ment Health
; 24(1): 119-131, 2021 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-32016551
8.
Efficacy of intravenous ketamine treatment in anxious versus nonanxious unipolar treatment-resistant depression.
Depress Anxiety
; 36(3): 235-243, 2019 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-30597688
9.
Recognition of emotional facial expressions in anxious and nonanxious depression.
Compr Psychiatry
; 70: 1-8, 2016 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-27624417
10.
A single infusion of ketamine improves depression scores in patients with anxious bipolar depression.
Bipolar Disord
; 17(4): 438-43, 2015 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-25400146
11.
Lithium and Valproate Levels Do Not Correlate with Ketamine's Antidepressant Efficacy in Treatment-Resistant Bipolar Depression.
Neural Plast
; 2015: 858251, 2015.
Artículo
en Inglés
| MEDLINE | ID: mdl-26137324
12.
Baseline working memory activation deficits in dimensional anxious depression as detected by magnetoencephalography.
Acta Neuropsychiatr
; 27(3): 143-52, 2015 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-25600154
13.
Ketamine's antidepressant efficacy is extended for at least four weeks in subjects with a family history of an alcohol use disorder.
Int J Neuropsychopharmacol
; 18(1)2014 Oct 31.
Artículo
en Inglés
| MEDLINE | ID: mdl-25539512
14.
Glutamate and its receptors in the pathophysiology and treatment of major depressive disorder.
J Neural Transm (Vienna)
; 121(8): 907-24, 2014 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-24318540
15.
Developing biomarkers in mood disorders research through the use of rapid-acting antidepressants.
Depress Anxiety
; 31(4): 297-307, 2014 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-24353110
16.
Biomarkers in mood disorders research: developing new and improved therapeutics.
Rev Psiquiatr Clin
; 41(5): 131-134, 2014.
Artículo
en Inglés
| MEDLINE | ID: mdl-26082563
17.
Neurobiology of anxious depression: a review.
Depress Anxiety
; 30(4): 374-85, 2013 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-23495126
18.
Defining anxious depression: a review of the literature.
CNS Spectr
; 18(5): 252-60, 2013 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-23507190
19.
Second messenger/signal transduction pathways in major mood disorders: moving from membrane to mechanism of action, part I: major depressive disorder.
CNS Spectr
; 18(5): 231-41, 2013 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-23462230
20.
Second messenger/signal transduction pathways in major mood disorders: moving from membrane to mechanism of action, part II: bipolar disorder.
CNS Spectr
; 18(5): 242-51, 2013 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-23472710